How TransCelerate streamlines trials

Monday, November 16, 2015

The Pulse on Site Success by Jeffrey Adelglass

Collaboration from industry leaders has led to many steps in the evolution of clinical trials and it is becoming significantly apparent that common goals to streamline many of the processes involved in conducting clinical research studies are critical. Simplifying the experience for investigators to allow more time for clinical activities is an important step toward achieving this goal.

[Read More]

Roche to restructure manufacturing network

Friday, November 13, 2015

Roche, based in Basel, Switzerland, has announced plans to restructure its manufacturing network for small molecules to address current underutilization as a result of its evolving portfolio. A new generation of specialized medicines based on small molecules requires novel manufacturing technologies and will be produced in lower volumes than traditional medicines.

[Read More]

Adheron Therapeutics is acquired by Roche

Monday, October 12, 2015

Adheron Therapeutics has been acquired by Roche. Adheron is a privately held biotechnology company developing SDP051, a product that disrupts cell adhesion which can potentially be used to treat inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic disease. SDP051 was fully humanized using Abzena’s Composite Human Antibody technology.

[Read More]

The perspective of the site as a silent partner

Monday, August 24, 2015

The Pulse on Site Success by Jeffrey Adelglass

If it has not become apparent to you over the last few years that the landscape is changing regarding the importance of a perspective site’s offer to sponsors and CROs, then one might infer you are missing the opportunity to better position your site for recognition and success.

[Read More]

Janus, Roche collaborate in autoimmune diseases

Friday, August 21, 2015

Janus Biotherapeutics, a Massachusetts-based autoimmunity therapeutics company, is collaborating with Roche on the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are class of proteins in the innate immune system. Evidence links aberrant TLR activation and signaling with the development of autoimmune disorders. Janus will work exclusively with Roche on TLR R&D.

[Read More]

Roche to acquire Kapa Biosystems

Thursday, August 20, 2015

Roche has signed a definitive agreement to acquire Kapa Biosystems, a privately held company based in Wilmington, Mass. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications.

[Read More]